Conduit Pharmaceuticals (CDT) announced key leadership changes to support the company’s next phase of growth and execution. Dr. Andrew Regan, the founder and initial financial backer of Conduit Pharmaceuticals, has been appointed Chief Executive Officer. He will succeed Dr. David Tapolczay, who is stepping down as CEO and as a member of the Board of Directors for personal reasons. Dr. Tapolczay will continue to serve the company as Head of Strategy & Licensing, ensuring continuity in strategic development and with an immediate focus on out-licensing deals for its tapinarof patents. The Company also announces that Faith Charles will be stepping down from the Board of Directors for personal reasons.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDT:
- Biotech Alert: Searches spiking for these stocks today
- Conduit Pharmaceuticals announces novel cocrystal patent filing for VTAMA
- Conduit Pharmaceuticals announces up to $1M share repurchase program
- Conduit expands parntership with Sarborg
- Conduit Pharmaceuticals receives U.S. patent approval for AZD1656